PPPrasad Patki

Prasad Patki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prasad Patki has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Towards sustainable multidisciplinary renal cancer tumour boards: redesigning the referral pathway

    by Bhargab Ghoshal, Sarika Nalagatla, Max Roberts, Adam Mann, David Cullen, Victoria Horsfall, Andrea Da Silva, Abhishek Reekhaye, Prasad Patki, Ravi Barod, et al.

    Objectives: To develop and evaluate a complexity‐stratified referral pathway aimed at improving the sustainability, efficiency and resource utilisation of specialist multidisciplinary team (SMDT) meetings within a high‐volume tertiary renal cancer service. Patients and Methods: We performed a retrospective cohort study of benign and malignant renal cancer cases discussed at SMDT meetings between January and December 2023 at the Royal Free Specialist Centre for Kidney Cancer. Patient demographics, tumour characteristics, SMDT discussions and management outcomes of patients were analysed to identify protocolised lower complexity cases suitable for alternative MDT pathways. Based on these findings, dedicated Standard of Care (SoC) and Benign MDTs were developed and implemented to manage lower complexity renal cases outside the main SMDT. The impact of the revised referral structure on SMDT workload, discussion efficiency and specialist resource utilisation was subsequently evaluated. Results: In 2023, 2228 patients with benign and malignant renal pathology underwent 4154 SMDT discussions. Most patients (96.3%) required under seven discussions. Patients aged >70 years with renal masses <2 cm frequently underwent repeated SMDT review, despite surveillance or conservative management representing the most common management recommendation. Bosniak I–II cysts were predominantly discharged, whilst Bosniak IIF cysts were mainly managed with surveillance. Following implementation of the revised referral structure incorporating SoC and Benign MDTs, cases discussed at the main SMDT decreased from a mean of 83 to 63 patients with cancer per week, whilst discussion time per patient increased by 30.8%. The revised pathway also reduced the requirement for full SMDT attendance for protocolised cases. Conclusion: Complexity‐stratified MDT referral structure improved efficiency and sustainability by diverting lower complexity protocolised cases to dedicated Benign and SoC MDTs. This enabled the main SMDT to prioritise clinically complex decision making and optimise utilisation of specialist multidisciplinary expertise.

  • High volume robotic assisted nephro-ureterectomy allows improved perioperative outcomes

    by N. Campain, A. Nathan, Y. Abu-Ghanem, M. Tran, P. Patki, F. Mumtaz, A. Bex, R. Barod

  • Open Access

    Growth and renal function dynamics of renal oncocytomas in patients on active surveillance

    by Joana B. Neves, Rebecca Varley, Stefano Agnesi, John Withington, Filipe B. Rodrigues, Hannah Warren, Yuigi Yuminaga, Umberto Capitanio, Nicola Rode, Lee Grant, et al.

    Objectives: To study the natural history of renal oncocytomas and address indications for intervention by determining how growth is associated with renal function over time, the reasons for surgery and ablation, and disease‐specific survival. Patients and Methods: The study was conducted in a retrospective cohort of consecutive patients with renal oncocytoma on active surveillance reviewed at the Specialist Centre for Kidney Cancer at the Royal Free London NHS Foundation Trust (2012 to 2019). Comparison between groups was performed using Mann–Whitney U ‐tests and chi‐squared tests. A mixed‐effects model with a random intercept for patient was used to study the longitudinal association between tumour size and estimated glomerular filtration rate (eGFR). Results: Longitudinal data from 98 patients with 101 lesions were analysed. Most patients were men (68.3%) and the median (interquartile range [IQR]) age was 69 (13) years. The median (IQR) follow‐up was 29 (26) months. Most lesions were small renal masses, and 24% measured over 4 cm. Over half (64.4%) grew at a median (IQR) rate of 2 (4) mm per year. No association was observed between tumour size and eGFR over time ( P = 0.871). Nine lesions (8.9%) were subsequently treated. Two deaths were reported, neither were related to the diagnosis of renal oncocytoma. Conclusion: Natural history data from the largest active surveillance cohort of renal oncocytomas to date show that renal function does not seem to be negatively impacted by growing oncocytomas, and confirms clinical outcomes are excellent after a median follow‐up of over 2 years. Active surveillance should be considered the 'gold standard' management of renal oncocytomas up to 7cm.


  • Open Access

    European Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high- risk among patients with renal tumours

    by Pranav Satish, Teele Kuusk, Nick Campain, Yasmin Abu-Ghanem, Joana Neves, Ravi Barod, Soha El-Sheikh, Faiz Mumtaz, Prasad Patki, Maxine Tran, et al.

    Introduction The purpose of prioritisation is to minimise harm while safeguarding access to health care in times of reduced resources. The EAU Guideline Office Rapid Reaction Group (GORRG) issued priority recommendations during the COVID-19 pandemic. We evaluated if the clinical prioritisation for suspected renal cell carcinoma (RCC) planned for surgery matched final pathological risk. Methods From 23 March 2020 until 10 October 2020, patients with suspected RCC were prioritised according to GORGG recommendations. To increase statistical power, GORGG prioritisation was also retrospectively assigned to pre-lockdown RCC surgical cases. The priority group was assessed according to GORGG guidelines, and postoperative risk was assessed according to 2003 Leibovich scores. We evaluated concordance between GORGG prioritisation and post-operative risk, and if stratification could be further improved by subgrouping of size. Results 351 patients with suspected RCC were prioritised and underwent surgery. The intermediate priority group showed poor concordance, with 25.7% and 16.4% being pathological low and high risk, respectively. The low priority group harboured 14.9% intermediate and 1.06% high risk RCC. Within the EAU intermediate group, 34.2% of cT1b tumours were low risk, and 32.3% of cT2a tumours high risk. Analysing at 1 cm increments, 45.1% of 4-5cm tumours were low risk. Conclusions The recommended prioritisation system can be error prone and should be prudently applied based on the centre’s needs. Particularly amongst the intermediate group, centres with clinical capacity should not defer intervention of cT2a tumours for longer than absolutely necessary and in severely limited resources may consider intermediate priority tumours < 5cm as low priority.

  • Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma

    by Joana B. Neves, Leyre Vanaclocha Saiz, Yasmin Abu-Ghanem, Marta Marchetti, My-Anh Tran-Dang, Soha El-Sheikh, Ravi Barod, Christian Beisland, Umberto Capitanio, David Cullen, et al.

    Purpose Currently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death. Methods Retrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015–2019) and the international collaborative database RECUR (15 institutes, 2006–2011). Kaplan–Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source. Results 295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death. Conclusion Recurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.


  • Open Access

    1869: Nuclear Magnetic Resonance Based Metabonomic Investigation of Semen, Urine and Plasma Metabolite Profiles in Healthy Volunteers and Men with Spinal Cord Injury

    by Prasad Patki, Michael Craggs, Julian Shah, Anthony Maher, John Lindon, Elaine Holmes, Olivier Cloarec, Jeremy Nicholson